MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press11710.17650/2782-3202-2024-4-2-71-77DIAGNOSTIC CAPABILITIESВОЗМОЖНОСТИ ДИАГНОСТИКИThe role of magnetic resonance imaging in cardio-oncologyРоль магнитно-резонансной томографии в кардиоонкологииhttps://orcid.org/0000-0003-4126-6078IvanovaZ. Z.ИвановаЗ. З.
Russian Federation

135 Rublevskoe Shosse, 121552 Moscow

121552 Москва, Рублевское шоссе, 135

https://orcid.org/0000-0002-7795-9709AlexandrovaS. A.АлександроваС. А.
Russian Federation

135 Rublevskoe Shosse, 121552 Moscow

121552 Москва, Рублевское шоссе, 135

https://orcid.org/0000-0003-1564-424XZeynalovaP. A.ЗейналоваП. А.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081,

Bld. 2, 8 Trubetskaya St., Moscow 119991

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111,

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0002-6395-5790AkhobekovA. A.АхобековА. А.
Russian Federation

Albert A. Akhobekov

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081,

Альберт Амалиевич Ахобеков 

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

alber-t7@mail.ruA.N. Bakulev National Medical Research Center for Cardiovascular Surgery, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава РоссииClinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)140620244271771406202414062024Copyright ©; 2024, ABV-PressCopyright ©; 2024, АБВ-пресс2024ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/117

In recent decades, groundbreaking methods of diagnosis and treatment were developed leading to significantly increased life span of patients with malignant neoplasms. Among patients treated for cancer, cardiovascular diseases are the leading cause of death not associated with cancer. Early identification of cardiotoxicity is very important as it allows to apply early prevention measures and modify antitumor treatment schemes. Prevention and treatment of cardiotoxicity are possible only with a functioning multidisciplinary team including oncologists and cardiologists. Magnetic resonance imaging of the heart plays a significant role in monitoring the condition of cardiovascular system during antitumor treatment. This technique allows to obtain accurate characteristics of the tissues and evaluate myocardial perfusion without radiation exposure.

В последние десятилетия появились прорывные методы диагностики и лечения, благодаря чему продолжительность жизни больных со злокачественными новообразованиями значительно увеличилась. Среди пациентов, вылеченных от рака, сердечно-сосудистые заболевания являются ведущей причиной смертности, не связанной с раком. Раннее выявление кардиотоксичности имеет важное значение, поскольку позволяет проводить раннюю профилактику и модифицировать схемы противоопухолевого лечения. Профилактика и лечение кардиотоксичности возможны только при функционировании мультидисциплинарной команды, включающей онкологов и кардиологов. Большое значение в мониторинге состояния сердечно-сосудистой системы на фоне противоопухолевого лечения имеет магнитно-резонансная томография сердца. Это исследование дает возможность получать точную характеристику тканей и оценивать перфузию миокарда без радиационной нагрузки.

 

cardio-oncologyantitumor therapycardiotoxicitymultidisciplinary teammagnetic resonance imagingкардиоонкологияпротивоопухолевая терапиякардиотоксичностьмультидисциплинарная командамагнитно-резонансная томографияSturgeon K.M., Deng L., Bluethmann S.M. et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40(48):3889–97. DOI: 10.1093/eurheartj/ehz766Armstrong G.T., Liu Q., Yasui Y. et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27(14):2328–38. DOI: 10.1200/JCO.2008.21.1425Plana J.C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15(10):1063–93. DOI: 10.1093/ehjci/jeu192Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–801. DOI: 10.1093/eurheartj/ehw211Armenian S.H., Hudson M.M., Mulder R.L. et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):e123–36. DOI: 10.1016/S1470-2045(14)70409-7Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215–21. DOI: 10.1200/JCO.2002.20.5.1215Schwartz R.G., McKenzie W.B., Alexander J. et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82(6):1109–18. DOI: 10.1016/0002-9343(87)90212-9Thavendiranathan P., Grant A.D., Negishi T. et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61(1):77–84. DOI: 10.1016/j.jacc.2012.09.035Otterstad J.E., Froeland G., St John Sutton M., Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997;18(3):507–13. DOI: 10.1093/oxfordjournals.eurheartj.a015273Armstrong G.T., Plana J.C., Zhang N. et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;30(23):2876–84. DOI: 10.1200/JCO.2011.40.3584Bellenger N.G., Burgess M.I., Ray S.G. et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000;21(16):1387–96. DOI: 10.1053/euhj.2000.2011Grothues F., Smith G.C., Moon J.C. et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90(1):29–34. DOI: 10.1016/s0002-9149(02)02381-0Suerken C.K., D’Agostino R.B. Jr., Jordan J.H. et al. Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2-year postchemotherapy measures of left ventricular ejection fraction. J Am Heart Assoc 2020;9(2):e015400. DOI: 10.1161/JAHA.119.015400Negishi T., Thavendiranathan P., Negishi K., Marwick T.H. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging 2018;11(8):1098–105. DOI: 10.1016/j.jcmg.2018.03.019Steen H., Montenbruck M., Wuelfing P. et al. P3118CMR Fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography. Eur Heart J 2019;40(Suppl_1);ehz745.0193. DOI: 10.1093/eurheartj/ehz745.0193Jolly M.P., Jordan J.H., Meléndez G.C. et al. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson 2017;19(1):59. DOI: 10.1186/s12968-017-0373-3Salem J.E., Manouchehri A., Moey M. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19(12):1579–89. DOI: 10.1016/S1470-2045(18)30608-9Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749–55. DOI: 10.1056/NEJMoa1609214Zhang L., Awadalla M., Mahmood S.S. et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020;7;41(18):1733–43. DOI: 10.1093/eurheartj/ehaa051Scriabina E.N., Safonova V.N., Agareva T.A. A rare case of Loeffler endocarditis associated with eosinophilic granulomatosis with polyangiitis. Saratovskiy nauchnomeditsinskiy zhurnal = Saratov Scientific Medical Journal 2017;13(4):823–8. (In Russ.).Скрябина Е.Н., Сафонова В.Н., Агарева Т.А. Редкий случай эндокардита Леффлера как проявление эозинофильного гранулематоза с полиангиитом. Саратовский научно-медицинский журнал 2017;13(4):823–8.Allderdice C., Marcu C., Kabirdas D. Intracardiac thrombus in leukemia: role of cardiac magnetic resonance imaging in eosinophilic myocarditis. CASE (Phila) 2018 Jun;2(3):114–7. DOI: 10.1016/j.case.2017.12.003Plácido R., Cunha Lopes B., Almeida A.G., Rochitte C.E. The role of cardiovascular magnetic resonance in takotsubo syndrome. J Cardiovasc Magn Reson 2016;18(1):68. DOI: 10.1186/s12968-016-0279-5Engblom H., Xue H., Akil S. et al. Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography. J Cardiovasc Magn Reson 2017;19(1):78. DOI: 10.1186/s12968-017-0388-9.Chaosuwannakit N., DʼAgostino R. Jr., Hamilton C.A. et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010;28(1):166–72. DOI: 10.1200/JCO.2009.23.8527Gertz M.A. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016;91(9): 947–56.Zhao L., Tian Z., Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:129. DOI: 10.1186/s12872-016-0311-6Motwani M., Kidambi A., Herzog B.A. et al. MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology 2013;268(1):26–43. DOI: 10.1148/radiol.13121239Cancer Research UK. Cancer survival statistic. Available at: https://www.cancerresearchuk.org/health-professional/ cancer-statistics/survival (accessed 15.10.2020).Lyon A.R., Dent S., Stanway S. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22(11):1945–60. DOI: 10.1002/ejhf.1920